Johnson & Johnson (NYSE:JNJ) Shares Sold by First Foundation Advisors

First Foundation Advisors reduced its position in Johnson & Johnson (NYSE:JNJ) by 7.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 47,050 shares of the company’s stock after selling 3,675 shares during the quarter. First Foundation Advisors’ holdings in Johnson & Johnson were worth $6,804,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. Principal Financial Group Inc. grew its position in shares of Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after acquiring an additional 329,473 shares in the last quarter. Financial Avengers Inc. increased its holdings in Johnson & Johnson by 3.0% during the 3rd quarter. Financial Avengers Inc. now owns 43,472 shares of the company’s stock worth $7,045,000 after purchasing an additional 1,276 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Johnson & Johnson during the third quarter worth approximately $242,000. TD Private Client Wealth LLC increased its stake in Johnson & Johnson by 41.3% in the third quarter. TD Private Client Wealth LLC now owns 33,076 shares of the company’s stock valued at $5,360,000 after acquiring an additional 9,671 shares during the last quarter. Finally, Soltis Investment Advisors LLC lifted its holdings in Johnson & Johnson by 3.7% in the third quarter. Soltis Investment Advisors LLC now owns 37,577 shares of the company’s stock valued at $6,090,000 after buying an additional 1,357 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.8 %

Shares of NYSE:JNJ opened at $149.82 on Thursday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $159.50 and a two-hundred day moving average of $155.37. The company has a market capitalization of $361.04 billion, a price-to-earnings ratio of 22.53, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the prior year, the business earned $2.29 earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Citigroup cut their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Eight research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.